EUVIMEDEUVIMED entdecken
Crossref

Empagliflozin alleviates hepatic ischemia-reperfusion injury by inhibiting c-Myc through the JAK1-STAT3 signaling pathway

Alimu Tulahong, Xinlu Xu, Tanfang Zhou, Rexiati Ruze, Zhongdian Yuan, Pingping Qiao, Tiemin Jiang, Tuerganaili Aji, Yingmei Shao

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.115508 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Alimu Tulahong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Hydatid Disease, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. Hauptthemen laut MEDLINE: Glucosides, Reperfusion Injury, Benzhydryl Compounds, Liver. Die Arbeit nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Department of Xinjiang Uygur Autonomous Region.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatic ischemia-reperfusion injury (HIRI) is a critical factor affecting the outcomes of liver surgeries, with inflammation and apoptosis playing pivotal roles in its pathogenesis. Empagliflozin, an anti-diabetic drug, has demonstrated hepatoprotective effects in various liver diseases, but its role in HIRI remains unclear. This study aimed to explore the protective mechanisms of empagliflozin against HIRI. Using rat HIRI models and Transformed Human Liver Epithelial-2 (THLE-2), we employed immunohistochemistry, ELISA, qRT-PCR, and Western blot to evaluate the effects of empagliflozin. Results showed that empagliflozin pretreatment significantly alleviated HIRI by reducing apoptosis and suppressing the secretion of inflammatory mediators. Hypoxia/reoxygenation experiments further confirmed that empagliflozin inhibited apoptosis and inflammation in THLE-2 cells. Mechanistically, empagliflozin downregulated JAK1-STAT3 signaling pathway and the c-Myc, which are critical in HIRI progression. These findings reveal that empagliflozin mitigates HIRI by suppressing JAK1-STAT3 pathway and the c-Myc, thereby reducing inflammation and apoptosis. This study highlights empagliflozin's potential as a prophylactic agent for HIRI, offering a scientific basis for its clinical application in liver transplantation and other contexts requiring HIRI prevention. By demonstrating empagliflozin's ability to modulate key signaling pathways, our research provides new insights into therapeutic strategies for HIRI, emphasizing its significance in hepatic preservation and clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesReperfusion InjuryBenzhydryl CompoundsLiverProto-Oncogene Proteins c-mycLiver DiseasesSodium-Glucose Transporter 2 InhibitorsAnimalsSTAT3 Transcription FactorJanus Kinase 1Signal TransductionHumansRatsApoptosisMaleCell LineRats, Sprague-Dawley

Stichwörter der Autor:innen

ApoptosisEmpagliflozinHepatic ischemia-reperfusion injuryInflammationJAK1-STAT3 signaling pathway

Substanzen

GlucosidesSTAT3 Transcription FactorJanus Kinase 1Benzhydryl CompoundsempagliflozinProto-Oncogene Proteins c-mycStat3 protein, ratJak1 protein, ratSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Hepatobiliary and Hydatid Disease, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
  • Department of Hepatobiliary and Hydatid Disease, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in…
  • Department of Hepatobiliary and Hydatid Disease, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. Electronic address: tuergan78@sina.com.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Department of Xinjiang Uygur Autonomous Region

Zitieren

APA

Tulahong, A., Xu, X., Zhou, T., Ruze, R., Yuan, Z., Qiao, P., Jiang, T., Aji, T., & Shao, Y. (2025). Empagliflozin alleviates hepatic ischemia-reperfusion injury by inhibiting c-Myc through the JAK1-STAT3 signaling pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115508

Vancouver

Tulahong A, Xu X, Zhou T, Ruze R, Yuan Z, Qiao P, et al. Empagliflozin alleviates hepatic ischemia-reperfusion injury by inhibiting c-Myc through the JAK1-STAT3 signaling pathway. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115508

BibTeX
@article{Tulahong2025,
  author = {Tulahong, Alimu and Xu, Xinlu and Zhou, Tanfang and Ruze, Rexiati and Yuan, Zhongdian and Qiao, Pingping and Jiang, Tiemin and Aji, Tuerganaili and Shao, Yingmei},
  title = {Empagliflozin alleviates hepatic ischemia-reperfusion injury by inhibiting c-Myc through the JAK1-STAT3 signaling pathway},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.115508}
}
Kostenlos starten →